Crossmark

Post-radiotherapy PET/CT for predicting treatment outcomes in head and neck cancer after postoperative radiotherapy

Crossref DOI link: https://doi.org/10.1007/s00259-019-4272-8

Published Online: 2019-01-24

Published Print: 2019-04

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Li, Yan

Awan, Musaddiq J. https://orcid.org/0000-0002-1063-7932
Chang, Tangel

Lavertu, Pierre

Zender, Chad

Rezaee, Rod

Fowler, Nicole

Wasman, Jay

Avril, Norbert E.

Chen, Nianyong

Machtay, Mitchell

Yao, Min
License Information

Text and Data Mining valid from 2019-01-24
More Information

Article History

Received: 22 August 2018

Accepted: 15 January 2019

First Online: 24 January 2019

Compliance with ethical standards

:

: Yan Li MD has no conflicts of interest. Musaddiq J. Awan MD has no conflicts of interest. Tangel Chang D.O. has no conflicts of interest. Pierre Lavertu MD has no conflicts of interest. Chad Zender MD has no conflicts of interest. Rod Rezaee MD has no conflicts of interest. Nicole Fowler MD has no conflicts of interest. Jay Wasman MD has no conflicts of interest. Norbert Avril, MD has no conflicts of interest. Nianyong Chen, MD PhD has no conflicts of interest. Mitchell Machtay MD reports that he is a consultant for Bristol-Myers, Abbvie and Novocure. Min Yao MD PhD has no conflicts of interest.

: This is a retrospective, minimal risk study. Institutional review board approval was obtained for retrospective review of patient charts. This was performed in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.